Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,340 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all

Conditions: Major Depressive Disorder
Interventions: Clopidogrel, LY2216684; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: LY3457263, Placebo, Dulaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Anniston, Alabama • Anaheim, California • South Miami, Florida + 2 more

Conditions: Healthy
Interventions: IMA-026; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: E6742, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer
Interventions: CX-2009; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more

Conditions: Diabetic Macular Edema, Uveitic Macular Edema
Interventions: RO7200220, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more

Conditions: Healthy
Interventions: Dr Pepper sweetened with sucrose or high fructose corn syrup; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Contraception, HIV
Interventions: Levonorgestrel and Ethinyl Estradiol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: Placebo, BI 409306; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Decitabine-THU; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anemia
Interventions: Sotatercept, Placebo; Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 24
States / cities: Azusa, California • Glendale, California • La Mesa, California + 16 more

Conditions: Healthy Participants
Interventions: CDX-622, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Solid Tumor
Interventions: ASN004; Drug
Lead sponsor: Kirilys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Atlanta, Georgia • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: AC0058TA, Placebo AC0058TA; Drug
Lead sponsor: ACEA Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Neoplasm Malignant
Interventions: SAR442257; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Duarte, California • Miami, Florida • Rochester, Minnesota

Conditions: Kidney Transplantation
Interventions: CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF), Corticosteroids (CS), anti-IL2 Induction; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Obesity, Tuberculosis
Interventions: Ethambutol; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: IgA Nephropathy
Interventions: BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Northridge, California • Denver, Colorado • Orlando, Florida + 6 more

Conditions: Alport Syndrome
Interventions: lademirsen (SAR339375), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more

Conditions: Systemic Lupus Erythematosus, Lupus Erythematosus
Interventions: Imvotamab; Drug
Lead sponsor: IGM Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: San Diego, California • San Leandro, California • DeBary, Florida + 4 more

Conditions: Mycosis Fungoides
Interventions: Pembrolizumab administered using the Sofusa® DoseConnect™; Combination Product
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hodgkin's Lymphoma
Interventions: TNX-650; Drug
Lead sponsor: Tanox; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Search by objective public record fields.

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Study Evaluating IMA-026 in Healthy Subjects

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

Pharmacokinetics and Pharmacodynamics of Fructose

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

A Phase I Study of CDX-622

Study of ASN004 in Patients With Advanced Solid Tumors

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma